Diagnosis of bone metastases in urological malignancies-an update

Urology

Volumn 76, Issue 4, 2010, Pages 782-790

  Rajarubendra, Nieroshan ^a   Bolton, Damien ^a   Lawrentschuk, Nathan ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM; ZOLEDRONIC ACID;

ADRENAL TUMOR; ALKALINE PHOSPHATASE BLOOD LEVEL; BLADDER CANCER; BONE BIOPSY; BONE METASTASIS; BONE SCINTISCANNING; CALCIUM BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; EARLY DIAGNOSIS; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HYPERCALCEMIA; KIDNEY CANCER; MALE; MEDICAL HISTORY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOLYSIS; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; QUALITY OF LIFE; RADIOGRAPHY; REVIEW; SYMPTOM; TESTIS CANCER;

ADRENAL GLAND NEOPLASMS; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE NEOPLASMS; BONE RESORPTION; CALCIUM; CARCINOMA; FEMALE; HUMANS; HYPERCALCEMIA; MAGNETIC RESONANCE IMAGING; MALE; OSTEOLYSIS; PHYSICAL EXAMINATION; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; TESTICULAR NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL; UROLOGIC NEOPLASMS;

EID: 77957751850     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.12.050     Document Type: Review

References (50)

1. G.D. Roodman Mechanisms of bone metastasis [see comment] N Engl J Med 350 2004 1655 1664
2. H. Al Husaini, P. Wheatley-Price, M. Clemons, and F.A. Shepherd Prevention and management of bone metastases in lung cancer: a review J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 4 2009 251 259
3. H.L. Abrams, R. Spiro, and N. Goldstein Metastases in carcinoma; analysis of 1000 autopsied cases Cancer 3 1950 74 85
4. D.I. Rosenthal Radiologic diagnosis of bone metastases Cancer 80 1997 1595 1607
5. J. Rigaud, R. Tiguert, N.L. Le, G. Karam, P. Glemain, J.-M. Buzelin, and O. Bouchot Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy J Urol 168 2002 1423 1426
6. A. Jemal, R. Siegel, E. Ward, T. Murray, J. Xu, and M.J. Thun Cancer statistics, 2007 CA Cancer J Clin 57 2007 43 66
7. G.R. Mundy Metastasis to bone: causes, consequences and therapeutic opportunities Nat Rev Cancer 2 2002 584 593
8. V. Vassiliou, and D. Kardamakis The management of metastatic bone disease with the combination of bisphosphonates and radiotherapy: from theory to clinical practice Curr Med Chem Anti Cancer Agents 9 2009 326 335
9. Saad F, Eastham J, McKiernan J and Congress. PatXEAoU: Long-term reduction of bone pain and skeletal morbidity with Zoledronic acid in patiets with prostate cancer and bone metastases (poster): XXth European Association of Urology Congress, European Association of Urology, 2005.
10. A. Fontana, and P.D. Delmas Markers of bone turnover in bone metastases Cancer 88 2000 2952 2960
11. R.A. Schaiff, T.G. Hall, and R.S. Bar Medical treatment of hypercalcemia Clin Pharmacol 8 1989 108 121
12. R. Vassilopoulou-Sellin, B.M. Newman, S.H. Taylor, and V.F. Guinee Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center Cancer 71 1993 1309 1312 (Pubitemid 23054924)
13. S. Conroy, and B. O'Malley Hypercalcaemia in cancer BMJ 331 2005 954
14. N.B. Watts Clinical utility of biochemical markers of bone remodeling Clin Chem 45 1999 1359 1368
15. T. Hamaoka, J.E. Madewell, D.A. Podoloff, G.N. Hortobagyi, and N.T. Ueno Bone imaging in metastatic breast cancer [see comment] J Clin Oncol 22 2004 2942 2953
16. M.L. Brown Bone scintigraphy in benign and malignant tumors Radiol Clin North Am 31 1993 731 738
17. T.A. Smith FDG uptake, tumour characteristics and response to therapy: a review Nucl Med Commun 19 1998 97 105
18. W. De Wever, J. Coolen, and J.A. Verschakelen Integrated PET/CT and cancer imaging Jbr-Btr: Organe de la societe Royale Belge de Radiologie 92 2009 13 19
19. E. Even-Sapir, U. Metser, G. Flusser, L. Zuriel, Y. Kollender, H. Lerman, G. Lievshitz, I. Ron, and E. Mishani Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT J Nucl Med 45 2004 272 278
20. Y. Nakamoto, C. Cohade, M. Tatsumi, D. Hammoud, and R.L. Wahl Appearance of bone metastases detected with FDG PET as part of the same PET/CT examination Radiology 237 2005 627 634
21. W. Langsteger, M. Heinisch, and I. Fogelman The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast Semin Nucl Med 36 2006 73 92
22. N. Lawrentschuk, I.D. Davis, D.M. Bolton, and A.M. Scott Diagnostic and therapeutic use of radioisotopes for bony disease in prostate cancer: current practice Int J Urol 14 2007 89 95
23. D. Vanel, J. Bittoun, and A. Tardivon MRI of bone metastases Eur Radiol 8 1998 1345 1351
24. V. Thomson, J.-B. Pialat, F. Gay, A. Coulon, A. Voloch, A. Granier, J.-C. Guerin, M. Viallon, and Y. Berthezene Whole-body MRI for metastases screening: a preliminary study using 3D VIBE sequences with automatic subtraction between noncontrast and contrast enhanced images Am J Clin Oncol 31 2008 285 292
25. H.J. Mankin, C.J. Mankin, and M.A. Simon The hazards of the biopsy, revisited Members of the musculoskeletal Tumor Society J Bone Joint Surg 78 1996 656 663
26. T.D. Peabody, and M.A. Simon Making the diagnosis: keys to a successful biopsy in children with bone and soft-tissue tumors Orthop Clin North Am 27 1996 453 459
27. M.A. Simon, and J.S. Biermann Biopsy of bone and soft-tissue lesions J Bone Joint Surg 75 1993 616 621
28. M.E. Oetgen, D.M. Grosser, G.E. Friedlaender, and D.M. Lindskog Core needle biopsies of musculoskeletal tumors: potential pitfalls 2008
29. R. Thurairaja, J. McFarlane, Z. Traill, and R. Persad State-of-the-art approaches to detecting early bone metastasis in prostate cancer BJU Int 94 2004 268 271
30. S. Abuzallouf, I. Dayes, and H. Lukka Baseline staging of newly diagnosed prostate cancer: a summary of the literature J Urol 171 2004 2122 2127
31. O. Akin, and H. Hricak Imaging of prostate cancer Radiol Clin North Am 45 2007 207 222
32. H. Schoder, and S.M. Larson Positron emission tomography for prostate, bladder, and renal cancer Semin Nucl Med 34 2004 274 292
33. C. Hofer, H. Kubler, R. Hartung, J. Breul, and N. Avril Diagnosis and monitoring of urological tumors using positron emission tomography Eur Urol 40 2001 481 487
34. H. Schirrmeister, A. Guhlmann, J. Kotzerke, C. Santjohanser, T. Kuhn, R. Kreienberg, P. Messer, K. Nussle, K. Elsner, and G. Glatting Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography J Clin Oncol 17 1999 2381 2389
35. E. Gosfield 3rd, A. Alavi, and B. Kneeland Comparison of radionuclide bone scans and magnetic resonance imaging in detecting spinal metastases [see comment] J Nucl Med 34 1993 2191 2198
36. F.E. Lecouvet, D. Geukens, A. Stainier, F. Jamar, J. Jamart, B.J. d'Othee, P. Therasse, B.B. Vande, and B. Tombal Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies J Clin Oncol 25 2007 3281 3287
37. S. Mani, M.B. Todd, K. Katz, and W.-J. Poo Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers J Urol 154 1995 35 40
38. O. Shvarts, J.S. Lam, H.L. Kim, K.R. Han, R. Figlin, and A. Belldegrun Eastern Cooperative Oncology Group Performance status predicts bone metastasis in patients presenting with renal cell carcinoma: implication for preoperative bone scans J Urol 172 2004 867 870
39. E. Seaman, E.T. Goluboff, S. Ross, and I.S. Sawczuk Association of radionuclide bone scan and serum alkaline phosphatase in patients with metastatic renal cell carcinoma Urology 48 1996 692 695
40. H.C. Wu, R.F. Yen, Y.Y. Shen, C.H. Kao, C.C. Lin, and C.C. Lee Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomasa preliminary report J Cancer Res Clin Oncol 128 2002 503 506
41. D.E. Kang, R.L. White Jr., J.H. Zuger, H.C. Sasser, and C.M. Teigland Clinical use of fluorodeoxyglucose F-18 positron emission tomography for detection of renal cell carcinoma J Urol 171 2004 1806 1809
42. P. Bhargava, M. Hanif, and C. Nash Whole-body F-18 sodium fluoride PET-CT in a patient with renal cell carcinoma Clin Nucl Med 33 2008 894 895
43. M.A. Saksena, D.M. Dahl, and M.G. Harisinghani New imaging modalities in bladder cancer World J Urol 24 2006 473 480
44. Jakse G, Algaba F, Fossa S, Stenzl A, Sternberg C. Guidelines on bladder cancermuscle-invasive and metastatic, European association of urology 2006.
45. P. Davey, M.V. Merrick, W. Duncan, and A.T. Redpath Bladder cancer: the value of routine bone scintigraphy Clin Radiol 36 1985 77 79
46. M. Braendengen, M. Winderen, and S.D. Fossa Clinical significance of routine pre-cystectomy bone scans in patients with muscle-invasive bladder cancer Br J Urol 77 1996 36 40
47. A. Lindner, and J.B. deKernion Cost-effective analysis of pre-cystectomy radioisotope scans J Urol 128 1982 1181 1182
48. C.S. Ng Radiologic diagnosis and staging of renal and bladder cancer Semin Roentgenol 41 2006 121 138
49. R.A. Huddart, M.J. O'Doherty, A. Padhani, G.J.S. Rustin, G.M. Mead, J.K. Joffe, P. Vasey, S.J. Harland, J. Logue, and G. Daugaard 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22the NCRI Testis Tumour Clinical Study Group J Clin Oncol 25 2007 3090 3095
50. K. Bouchelouche, and P. Oehr Recent developments in urologic oncology: positron emission tomography molecular imaging Curr Opin Oncol 20 2008 321 326